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Identity 
Other names: HSULF-2 




SULF2 55959 chr 20: 46286150-46415360. The gene 
encompasses 130 kb of DNA; 21 exons. 
Transcription 
3 transcripts: transcript variant 1, 3909 bp linear 
mRNA, 21 exons (NM_018837); transcript variant 2, 
4239 bp linear mRNA, 21 exons (NM_198596); 




870 amino acid; 100 kDa protein; post translational 
modification: 11 N-glycosylation sites; contains from 
N-term to C-term, a signal peptide (1-24), a enzymatic 
domain (25-400) which contains a  
conserved cysteine (88) essential for the catalytic 
activity, a hydrophilic domain (401-739) which 
contains four lysines and arginies rich domains suited 
for interactions with sulfated HSGAGs that fit the 
heparin-binding motif, and a glucosamine-6-sulfatase 
domain (740-870). 
Expression 
Widely expressed, especially in ovary, skeletal muscle, 
stomach, brain, uterus, heart, kidney, and placenta. 
Localisation 
Extracellular space, cell surface, plasma membrane, 
endoplasmic reticulum, and Golgi stack. 
Function 
SULF2 is a member of a novel family of extracellular 
HS 6-O endosulfatases with heparin-degrading 
endosulfatase activity. SULF2 desulfates HS and 
increases the local concentration of growth factors in 
the extracellular matrix. The released growth factors 
then bind to their cell surface receptors, with the 
consequent activation of cell growth and survival 
pathways in HCC. SULF2 up-regulated GPC3 




Schematic diagram of SULF2 with domains. 






Atlas Genet Cytogenet Oncol Haematol. 2013; 17(10)  714 
 
 
It has been shown that SULF2 liberates growth factors 
such as Wnt3a from HSPGs such as GPC3 on the cell 
surface and in the extracellular matrix by desulfating 
heparan sulfate (HS).  
It has been reported that SULF2 mRNA is up-regulated 
in human breast cancers, and suppression of SULF2 
expression decreases tumorigenesis of pancreatic 
cancer cell lines.  
SULF2 regulates PDGFRα signaling and growth in 
malignant glioma. 
Homology 
Conserved in Rhesus monkey, dog, cow, mouse, rat, 
chicken, and zebrafish. 
Mutations 
Somatic 
Identified mutations in various cancers. 
Implicated in 
Hepatocellular carcinoma (HCC) 
Prognosis 
In a microarray experiment performed on paired benign 
and tumor tissues from HCC patients, SULF2 
expression was higher in the tumors than in the benign 
tissues in 79 (57%) of 139 HCCs. Patients with tumors 
expressing high SULF2 levels had a significantly 
poorer prognosis than those with tumor expressing low 
SULF2 levels (Lai et al., 2008a). 
Oncogenesis 
Expression of SULF2 promotes HCC cell proliferation 
and migration. Knockdown of SULF2 decreases HCC 
cell proliferation and migration. SULF2 promotes 
tumorigenesis in nude mice and up-regulates GPC3 in 
vivo (Lai et al., 2008a). 
Lung cancer 
Prognosis 
Paired samples of lung squamous carcinoma and non 
malignant neighboring tissue were obtained from 10 
patients undergoing surgical resection. SULF2 
increased in 8/10 pairs with a mean increase of 3 ± 0.3-
fold. qPCR analysis of SULF2 in  
archived cases of lung carcinoma verified it. SULF2 
increased 4 ± 0.3 fold in squamous carcinomas and 3 ± 
0.4 fold in adenocarcinomas (Lemjabbar-Alaoui et al., 
2010). 
Oncogenesis 
Knockdown of SULF2 or expression of dominant-
negative SULF2 reduces growth of lung cancer cells.  
SULF2 over-expression in non-malignant bronchial 
epithelial cells induces a transformed phenotype in 
culture.  
SULF2 knockdown reduces growth of tumors arising 
from lung cancer cells (Lemjabbar-Alaoui et al., 2010). 
Glioblastoma (GBM) 
Prognosis 
SULF2 expression is elevated in GBM. Unsing a 
stringent cutoff of a 10-fold increase in SULF2 SAGE 
tags over levels in normal brain to define high SULF2 
levels, 7 of 16 GBMs has increased SULF2 expression.  
Strikingly, in an independent set of 424 primary human 
GBM tumors, SULF2 expression was increased in 46% 
(197/424) of tumors related to normal brain.  
Immunohistochemistry on an independent set of 57 
primary human GBM tumors demonstrated SULF2 
protein in tumor cells in 50% of tumors.  
SULF2 expression is associated with the proneural 
subtype of GBM characterized by abnormalities in the 
PDGFRα-signaling pathway and SULF2 expression is 
associated with the proneural GBM subtype (Phillips et 
al., 2012). 
Oncogenesis 
SULF2 confers a growth advantage to human GBM 
cells, SULF2 knockdown resulted in a significant 
decrease in cell viability.  
SULF2 also confers a growth advantage to human 
GBM cells in vivo. SULF2 confers increased 
tumorigenicity and proliferation.  
Prolonged survival confered by ablation of SULF2 in 
tumorigenic neurospheres.  
And absence of SULF2 resulted in decreased tumor cell 
proliferation in vivo (Phillips et al., 2012). 











Fusion of ARFGEF2 exon 1 to SULF2 exons 3-21. 
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